Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | AKT1 | P31749 | 2/20 | 0.44 |
| ▸ | CTSS | P25774 | 4/20 | 0.44 |
| ▸ | CTSK | P43235 | 2/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1951666 | 1.00 | CA12 (0.47) | CA12CA1CA7CA14ATM | |
| SCHEMBL1951583 | 1.00 | CA12 (0.47) | CA12CA1CA7CA14ATM | |
| SCHEMBL2953653 | 0.91 | CTSS (0.46) | CA12CA1CA7CA14ATM | |
| SCHEMBL2953651 | 0.91 | CTSS (0.46) | CA12CA1CA7CA14ATM | |
| SCHEMBL13099832 | 0.88 | KCNN4 (0.44) | CA12CA1CA7CA14ATM | |
| SCHEMBL19331927 | 0.87 | MIF (0.47) | CA12CA1CA7CA14ATM | |
| SCHEMBL4221670 | 0.87 | MIF (0.47) | CA12CA1CA7CA14ATM | |
| SCHEMBL27159397 | 0.87 | PPARA (0.41) | CA12CA1CA7CA14ATM | |
| SCHEMBL20608008 | 0.87 | KCNN4 (0.51) | CA12CA1CA7CA14ATM | |
| SCHEMBL27159394 | 0.87 | PPARA (0.41) | CA12CA1CA7CA14ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113121396-B | Degradable polydiseleno-containing polydopamine and preparation method and application thereof | 华南理工大学 | 2022-06-10 | — | — | CN | claimed |
| EP-4332089-A1 | METHOD FOR PREPARING AMINO ACIDS | PHILIPPS-UNIVERSITÄT MARBURG (DE) | 2024-03-06 | — | — | EP | disclosed |
| US-11851434-B2 | Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-12-26 | — | — | US | disclosed |
| WO-2023226965-A1 | ROCK INHIBITORS AND USES THEREOF | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-11-30 | — | — | WO | disclosed |
| EP-3571203-B1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-4067355-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYME (DUB) INHIBITORS | Mission Therapeutics Limited (GB) | 2022-10-05 | — | — | EP | disclosed |
| CN-113121396-B | Degradable polydiseleno-containing polydopamine and preparation method and application thereof | 华南理工大学 | 2022-06-10 | — | — | CN | disclosed |
| EP-3423454-B1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2022-05-25 | — | — | EP | disclosed |
| CN-111647036-B | Ocotillol esterified derivatives, preparation method thereof and application thereof in preparing anti-inflammatory drugs | 烟台大学 | 2022-05-13 | — | — | CN | disclosed |
| CN-110267960-B | Substituted pyrazolo [1,5-a ] pyrazine compounds as RET kinase inhibitors | 阿雷生物药品公司 | 2022-04-26 | — | — | CN | disclosed |
| US-7432258-B2 | Morpholinyl and pyrrolidinyl analogs | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432258-B2 | Morpholinyl and pyrrolidinyl analogs | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-20080021023-A1 | 4'-[(1R)-1-[[(6,7-dichloro-3-oxo-2,3-dihydro-4H-1,4-benzoxazin- 4-yl)acetyl](methyl)amino]-2-(4-morpholinyl)ethyl]-4-biphenylcarboxylic acid; as antagonists of urotensin II, congestive heart failure, stroke, ischemic heart disease (e.g. angina, myocardial ischemia), cardiac arrhythmia, hypertension | GLAXOSMITHKLINE LLC | 2008-01-24 | — | — | US | disclosed |
| US-20080021023-A1 | 4'-[(1R)-1-[[(6,7-dichloro-3-oxo-2,3-dihydro-4H-1,4-benzoxazin- 4-yl)acetyl](methyl)amino]-2-(4-morpholinyl)ethyl]-4-biphenylcarboxylic acid; as antagonists of urotensin II, congestive heart failure, stroke, ischemic heart disease (e.g. angina, myocardial ischemia), cardiac arrhythmia, hypertension | GLAXOSMITHKLINE LLC | 2008-01-24 | — | — | US | disclosed |
| EP-0692982-B1 | RADIOLABELED PLATELET GPIIb/IIIa RECEPTOR ANTAGONISTS AS IMAGING AGENTS FOR THE DIAGNOSIS OF THROMBOEMBOLIC DISORDERS | DU PONT PHARM CO (US) | 2000-07-05 | — | — | EP | disclosed |
| EP-0995761-A2 | Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders | Dupont Pharmaceuticals Company (US) | 2000-04-26 | — | — | EP | disclosed |
| US-6022523-A | NOVEL CYCLIC COMPOUNDS CONTAINING CARBOCYCLIC AND HETEROCYCLIC RING SYSTEMS | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-02-08 | — | — | US | disclosed |
| US-5879657-A | Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1999-03-09 | — | — | US | disclosed |
| US-5674864-A | ANALGESICS; ENDOPEPTIDASE AND ENKEPHALINASE INHIBITORS; CARDIOTONIC, PSYCHOTROPIC AND HYPERTENSIVE AGENTS | ROUSSEL UCLAF (FR) | 1997-10-07 | — | — | US | disclosed |
| US-5190974-A | Analgesics | ROUSSEL UCLAF (FR) | 1993-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11851434-B2 | Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors | RET, BRAF, ROR1 | CA12 4331/4885CA1 3306/4885CA7 3540/4885 |
| US-20080021023-A1 | 4'-[(1R)-1-[[(6,7-dichloro-3-oxo-2,3-dihydro-4H-1,4-benzoxazin- 4-yl)acetyl](methyl)amino]-2-(4-morpholinyl)ethyl]-4-biphenylcarboxylic acid; as antagonists of urotensin II, congestive heart failure, stroke, ischemic heart disease (e.g. angina, myocardial ischemia), cardiac arrhythmia, hypertension | UTS2R, PLAUR, FABP3 | CA12 3689/4885CA1 1803/4885CA7 2999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.